🎯 check Trametinib (GSK1120212) product page
Trametinib (GSK1120212) is a highly selective, reversible allosteric MEK1/2 inhibitor. It affects the MAPK/ERK signaling pathway by preventing RAF-dependent MEK phosphorylation and suppressing ERK activation to inhibit tumor cell proliferation, migration, and induce apoptosis.